A small-molecule RGD-integrin antagonist inhibits cell adhesion, cell migration and induces anoikis in glioblastoma cells

International Journal of Oncology

Volumn 42, Issue 1, 2013, Pages 83-92

  Russo, Marika A ^a   Paolillo, Mayra ^b   Sanchez Hernandez, Yuly ^b   Curti, Daniela ^b   Ciusani, Emilio ^c   Serra, Massimo ^b   Colombo, Lino ^b   Schinelli, Sergio ^b  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF PAVIA   (Italy)

^c DEPARTMENT OF NEUROSURGERY   (Italy)

Author keywords

Anoikis; Glioblastoma; Integrins; Migration

Indexed keywords

1 A ARGINYLGLYCYLASPARTIC ACID; ANNEXIN; ARGINYLGLYCYLASPARTIC ACID; FOCAL ADHESION KINASE; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; UNCLASSIFIED DRUG;

ACTIN FILAMENT; ANOIKIS; ARTICLE; CELL ADHESION; CELL PROLIFERATION; CELL VIABILITY; GLIOBLASTOMA; HUMAN; HUMAN CELL; MIGRATION INHIBITION; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; STAINING; TUMOR CELL LINE;

ACTIN CYTOSKELETON; ANOIKIS; BLOTTING, WESTERN; BRAIN NEOPLASMS; CELL ADHESION; CELL MOVEMENT; CELL PROLIFERATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FOCAL ADHESION PROTEIN-TYROSINE KINASES; GLIOBLASTOMA; HUMANS; IMMUNOENZYME TECHNIQUES; INTEGRIN ALPHAVBETA3; OLIGOPEPTIDES; PHOSPHORYLATION; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, VITRONECTIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED;

EID: 84873627346     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2012.1708     Document Type: Article

References (28)

1. Paolillo M, Russo MA, Serra M, Colombo L and Schinelli S: Small molecule integrin antagonists in cancer therapy. Mini Rev Med Chem 9: 1439-1446, 2009.
2. Schnell O, Krebs B, Wagner E, Romagna A, Beer AJ, Grau SJ, Thon N, Goetz C, Kretzschmar HA, Tonn JC and Goldbrunner RH: Expression of integrin ανβ3 in gliomas correlates with tumor grade and is not restricted to tumor vasculature. Brain Pathol 18: 378-386, 2008. (Pubitemid 351782847)
3. Zhao J and Guan JL: Signal transduction by focal adhesion kinase in cancer. Cancer Metastasis Rev 28: 35-49, 2009.
4. Assoian RK and Klein EA: Growth control by intracellular tension and extracellular stiffness. Trends Cell Biol 18: 347-352, 2008.
5. Yamada S, Bu XY, Khankaldyyan V, Gonzales-Gomez I, McComb JG and Laug WE. Effect of the angiogenesis inhibitor cilengitide (EMD 121974) on glioblastoma growth in nude mice. Neurosurgery 59: 1304-1312, 2006. (Pubitemid 44949775)
6. Reardon DA, Fink KL, Mikkelsen T, Cloughesy TF, O'Neill A, Plotkin S, Glantz M, Ravin P, Raizer JJ, Rich KM, Schiff D, Shapiro WR, Burdette-Radoux S, Dropcho EJ, Wittemer SM, Nippgen J, Picard M and Nabors LB: Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme. J Clin Oncol 26: 5610-5617, 2008.
7. Stupp R, Hegi ME, Neyns B, Goldbrunner R, Schlegel U, Clement PM, Grabenbauer GG, Ochsenbein AF, Simon M, Dietrich PY, Pietsch T, Hicking C, Tonn JC, Diserens AC, Pica A, Hermisson M, Krueger S, Picard M and Weller M: Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. J Clin Oncol 28: 2712-2718, 2010.
8. Arosio D, Belvisi L, Colombo L, Colombo M, Invernizzi D, Manzoni L, Potenza D, Serra M, Castorina M, Pisano C and Scolastico C: A potent integrin antagonist from a small library of cyclic RGD pentapeptide mimics including benzyl-substituted azabicycloalkane amino acids. Chem Med Chem 3: 1589-1603, 2008.
9. Paolillo M, Russo MA, Curti D, Lanni C and Schinelli S: Endothelin B receptor antagonists block proliferation and induce apoptosis in glioma cells. Pharmacol Res 61: 306-315, 2010.
10. Dussault AA and Pouliot M: Rapid and simple comparison of messenger RNA levels using real-time PCR. Biol Proced Online 8: 1-10, 2006. (Pubitemid 43173726)
11. Wehrle-Haller B: Assembly and disassembly of cell matrix adhesions. Curr Opin Cell Biol: July 19, 2012 (Epub ahead of print).
12. Hanahan D and Weinberg RA: Hallmarks of cancer: the next generation. Cell 144: 646-674, 2011.
13. Desgrosellier JS and Cheresh DA: Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer 10: 9-22, 2010.
14. Reynolds AR, Hart IR, Watson AR, Welti JC, Silva RG, Robinson SD, Da Violante G, Gourlaouen M, Salih M, Jones MC, Jones DT, Saunders G, Kostourou V, Perron-Sierra F, Norman JC, Tucker GC and Hodivala-Dilke KM: Stimulation of tumor growth and angiogenesis by low concentrations of RGD-mimetic integrin inhibitors. Nat Med 15: 392-400, 2009.
15. Belvisi L, Bernardi A, Colombo M, Manzoni L, Potenza D, Scolastico C, Giannini G, Marcellini M, Riccioni T, Castorina M, LoGiudice P and Pisano C: Targeting integrins: insights into structure and activity of cyclic RGD pentapeptide mimics containing azabicycloalkane amino acids. Bioorg Med Chem 14: 169-180, 2006. (Pubitemid 41635481)
16. Maglott A, Bartik P, Cosgun S, Klotz P, Ronde P, Fuhrmann G, Takeda K, Martin S and Dontenwill M: The small alpha5beta1 integrin antagonist, SJ749, reduces proliferation and clonogenicity of human astrocytoma cells. Cancer Res 66: 6002-6007, 2006.
17. Mattern RH, Read SB, Pierschbacher MD, Sze CI, Eliceiri BP and Kruse CA: Glioma cell integrin expression and their interactions with integrin antagonists. Cancer Ther 3A: 325-340, 2005.
18. Maurer GD, Tritschler I, Adams B, Tabatabai G, Wick W, Stupp R and Weller M: Cilengitide modulates attachment and viability of human glioma cells, but not sensitivity to irradiation or temozolomide in vitro. Neurooncology 11: 747-756, 2009.
19. Schaller MD: Cellular functions of FAK kinases: insight into molecular mechanisms and novel functions. J Cell Sci 123: 1007-1013, 2010.
20. Oliveira-Ferrer L, Hauschild J, Fiedler W, Bokemeyer C, Nippgen J, Celik I and Schuch G: Cilengitide induces cellular detachment and apoptosis in endothelial and glioma cells mediated by inhibition of FAK/src/AKT pathway. J Exp Clin Cancer Res 27: 86, 2008.
21. Kuphal S, Bauer R and Bosserhoff AK: Integrin signaling in malignant melanoma. Cancer Metastasis Rev 24: 195-222, 2005. (Pubitemid 40922795)
22. Puissant A, Dufies M, Fenouille N, Ben Sahra I, Jacquel A, Robert G, Cluzeau T, Deckert M, Tichet M, Chéli Y, Cassuto JP, Raynaud S, Legros L, Pasquet JM, Mahon FX, Luciano F and Auberger P: Imatinib triggers mesenchymal-like conversion of CML cells associated with increased aggressiveness. J Mol Cell Biol 4: 207-220, 2012.
23. Bianchi-Smiraglia A, Paesante S and Bakin AV: Integrin β5 contributes to the tumorigenic potential of breast cancer cells through the Src-FAK and MEK-ERK signaling pathways. Oncogene: July 23, 2012 (Epub ahead of print) doi: 10.1038/onc.2012.320.
24. Muller PA, Caswell PT, Doyle B, Iwanicki MP, Tan EH, Karim S, Lukashchuk N, Gillespie DA, Ludwig RL, Gosselin P, Cromer A, Brugge JS, Sansom OJ, Norman JC and Vousden KH: Mutant p53 drives invasion by promoting integrin recycling. Cell 139: 1327-1341, 2009.
25. Martinkova E, Maglott A, Leger DY, Bonnet D, Stiborova M, Takeda K, Martin S and Dontenwill M: alpha5beta1 integrin antagonists reduce chemotherapy-induced premature senescence and facilitate apoptosis in human glioblastoma cells. Int J Cancer 127: 1240-1248, 2010.
26. Xu J, Millard M, Ren X, Cox OT and Erdreich-Epstein A: c-Abl mediates endothelial apoptosis induced by inhibition of integrins alphavbeta3 and alphavbeta5 and by disruption of actin. Blood 115: 2709-2718, 2010.
27. Braun K, Wiessler M, Pipkorn R, Ehemann V, Bauerle T, Fleischhacker H, Muller G, Lorenz P and Waldeck W: A cyclic-RGD-BioShuttle functionalized with TMZ by DARinv 'Click Chemistry' targeted to ανβ3 integrin for therapy. Int J Med Sci 7: 326-339, 2010.
28. Pollard SM, Yoshikawa K, Clarke ID, Danovi D, Stricker S, Russell R, Bayani J, Head R, Lee M, Bernstein M, Squire JA, Smith A and Dirks P: Glioma stem cell lines expanded in adherent culture have tumor-specific phenotypes and are suitable for chemical and genetic screens. Cell Stem Cell 4: 568-580, 2009.